Page last updated: 2024-12-04

acetyl-dl-leucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

acetylleucine: used for treating vestibular-related imbalance and vertigo [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1995
CHEMBL ID1875805
CHEBI ID166830
SCHEMBL ID282371
MeSH IDM0391682

Synonyms (82)

Synonym
EU-0067605
MLS002207045
smr001306703
OPREA1_806534
CHEBI:166830
acetyl-dl-leucine
99-15-0
n-acetyl-dl-leucine
dl-leucine, n-acetyl-
nsc122020
nsc-122020
nsc-203436
nsc203436
acetylleucine
tanganil (tn)
acetylleucine (inn)
D07350
nsc206316
l-leucine, n-acetyl-
nsc-206311
nsc-206316
nsc206311
A0097
ac-dl-leu-oh
HMS1607L21
2-acetamido-4-methylpentanoic acid
STK803086
tanganil
AKOS000132161
unii-k76s41v71x
nsc 758152
acetylleucinum
k76s41v71x ,
acetileucina [spanish]
acetylleucine [inn]
nsc 122020
einecs 202-734-9
rp 7452
(r,s)-n-acetylleucin
acetylleucinum [latin]
acetileucina
BBL012196
nsc-758152
CHEMBL1875805
acetylleucine, dl-
2-(acetylamino)-4-methylpentanoic acid
FT-0602607
FT-0624387
FT-0629837
AM20120403
acetylleucine [mi]
acetylleucine [mart.]
acetylleucine [who-dd]
F0777-0821
SCHEMBL282371
AKOS016039425
CS-4647
SY013106
Q-100915
n-acetylleucine #
leucine, n-acetyl-, dl-
FD20065
AC-24095
HY-B1442
mfcd00026498
SR-01000391875-2
SR-01000391875-3
sr-01000391875
SR-01000391875-1
SY008073
Q2823840
DB13226
n-acetyl-d,l-leucine
AS-14331
DTXSID40859594
acetyl dl-leucine
M03064
acetylleucine (isomer of 164)
SY062212
n-acetyl-d-leucine??
EN300-297596
Z56755951

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" No treatment-related serious adverse events occurred."( Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.
Bremova-Ertl, T; Claassen, J; Foltan, T; Gascon-Bayarri, J; Gissen, P; Hahn, A; Hassan, A; Hennig, A; Jones, SA; Kolnikova, M; Martakis, K; Raethjen, J; Ramaswami, U; Schneider, SA; Sharma, R, 2022
)
0.72
" NALL was safe and well-tolerated, informing a favorable benefit-risk profile for the treatment of NPC."( Efficacy and safety of N-acetyl-L-leucine in Niemann-Pick disease type C.
Bremova-Ertl, T; Claassen, J; Foltan, T; Gascon-Bayarri, J; Gissen, P; Hahn, A; Hassan, A; Hennig, A; Jones, SA; Kolnikova, M; Martakis, K; Raethjen, J; Ramaswami, U; Schneider, SA; Sharma, R, 2022
)
0.72
" NALL was safe and well tolerated, contributing to an overall favorable risk:benefit profile."( Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses.
Bremova-Ertl, T; Claassen, J; Gascon-Bayari, J; Goldschagg, N; Hahn, A; Hassan, A; Hennig, A; Jones, S; Kay, R; Lau, H; Martakis, K; Perlman, S; Schneider, S; Sharma, R, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
"The enantiomers of many chiral drugs not only exhibit different pharmacological effects in regard to targets that dictate therapeutic and toxic effects, but are also handled differently in the body due to pharmacokinetic effects."( Unexpected differences in the pharmacokinetics of N-acetyl-DL-leucine enantiomers after oral dosing and their clinical relevance.
Churchill, GC; Galione, A; Platt, FM; Strupp, M, 2020
)
0.81

Dosage Studied

ExcerptRelevanceReference
"In this large multicenter, double-blind, randomized, placebo-controlled clinical crossover trial, acetyl-DL-leucine in the investigated dosage and treatment duration was not superior to placebo for the symptomatic treatment of certain types of ataxia."( Safety and Efficacy of Acetyl-DL-Leucine in Certain Types of Cerebellar Ataxia: The ALCAT Randomized Clinical Crossover Trial.
Adrion, C; Boesch, S; Doss, S; Feil, K; Giordano, I; Hengel, H; Jacobi, H; Klockgether, T; Klopstock, T; Mansmann, U; Nachbauer, W; Naumann, I; Schöls, L; Steiner, KM; Stendel, C; Strupp, M; Timmann, D, 2021
)
1.15
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
leucine derivativeAn amino acid derivative resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of leucine by a heteroatom. The definition normally excludes peptides containing leucine residues.
N-acetyl-amino acidAn N-acyl-amino acid that has acetyl as the acyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.20600.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (65)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (4.62)18.7374
1990's6 (9.23)18.2507
2000's10 (15.38)29.6817
2010's27 (41.54)24.3611
2020's19 (29.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.50 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index66.91 (26.88)
Search Engine Supply Index3.83 (0.95)

This Compound (29.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (10.61%)5.53%
Reviews5 (7.58%)6.00%
Case Studies5 (7.58%)4.05%
Observational2 (3.03%)0.25%
Other47 (71.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]